0 results for 'Eli Lilly'
Big Names Brandished in Effort to Restore $1.2B Cancer Treatment Verdict
The Federal Circuit ruled that a patent on a CAR-T treatment did not meet patent law's written description requirement. Jones Day and Irell & Manella are arguing for Bristol-Myers Squibb that the Federal Circuit has added judicial requirements to the statute that are virtually impossible for life sciences companies to meet.An Early-Week Batch of Litigator of the Week Shout Outs
With two weeks' worth of wins under consideration in this cycle of Litigator of the Week, we're giving a little extra shine to a worthy batch of shout outs.Pharma Company Sues to Block Blockchain Medical Platform From Using 'LY' for Cryptocurrency
This lawsuit was surfaced on Law.com Radar. Read the complaint here.With Billions at Stake, Supreme Court Dips Its Toes Into Biologic Drug Patents
The justices have asked for the solicitor general's views on a cert petition by Amgen in a case that could reinterpret patent law's Section 112 and the law of enablement.View more book results for the query "Eli Lilly"
The Benefits, Consequences and Pitfalls of Terminal Disclaimers
A terminal disclaimer—a seemingly simple document that shortens a patent's life by declaring that it expires upon the expiration of another commonly owned patent—is replete with technical and substantive traps for the unwary and far-reaching consequences during both prosecution and enforcement of U.S. patents.Federal Judge Allows Teva's Migraine Med Patent Lawsuit to Proceed Against Eli Lilly
Teva argues that Eli Lilly induced infringement of two of Teva's patents that protect the methods for administering the drug for the treatment of "refractory" migraines, or for patients who failed on at least two prior migraine preventative treatments.Federal Circuit Underscores Importance of Written Description Requirement
'Biogen Int'l GMBH v. Mylan Pharms.' highlights the importance of considering invalidity under the written description requirement as a potential defense in litigation—particularly in ANDA cases, in which therapeutic efficacy for specific conditions, and drugs dosage amounts, may be at issue—and for patent applicants to remain mindful of written description pitfalls throughout patent prosecution.DeSantis Blasts FDA For Halting Drugs Ineffective on Omicron
The FDA says omicron is responsible for more than 99% of U.S. infections, making it "highly unlikely" that the antibodies would be effective for people seeking treatment.Run It Back! One Last Look at the 2021 Litigators of the Week
Here's one last 'huzzah!' for this year's winners.Corporate Transparency Act Resource Kit
Brought to you by Wolters Kluwer
Download Now
Revenue, Profit, Cash: Managing Law Firms for Success
Brought to you by Juris Ledger
Download Now
Law Firm Operational Considerations for the Corporate Transparency Act
Brought to you by Wolters Kluwer
Download Now
The Ultimate Guide to Remote Legal Work
Brought to you by Filevine
Download Now